Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

被引：0
|
作者：
Ratnayake, G. M. [1 ]
Koffas, A. [1 ]
Theocharopoulos, I [1 ]
Hayes, A. [1 ]
Navalkissoor, S. [1 ]
Gnanasegaran, G. [1 ]
Quigley, A. M. [1 ]
Khoo, B. [1 ]
Mandair, D. [1 ]
Grossman, A. [1 ]
Caplin, M. [1 ]
Alsadik, S. [1 ]
Clark, R. [1 ]
Toumpanakis, C. [1 ]
机构：
[1] Royal Free Hosp, ENETS Ctr Excellence, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
carcinoid syndrome; prrt;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H24
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [31] Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy
    Van Wyk, Bronwin
    Hasford, Francis
    Nyakale, Nozipho
    Vangu, Mboyo-Di-Tamba
    HEALTH AND TECHNOLOGY, 2024, 14 (02) : 277 - 289
  • [32] Peptide receptor radionuclide therapy with lutetium-177 DOTATATE in a case of recurrent extradrenal retroperitoneal malignant paraganglioma with nodal and bone metastasis
    Kamaleshwaran, Koramadai Karuppusamy
    Subramaniam, Paulvannan
    Natarajan, Sudhakar
    Velayutham, Pavanasam
    Mohanan, Vyshak
    Shinto, Ajit Sugunan
    CLINICAL CANCER INVESTIGATION JOURNAL, 2015, 4 (01): : 84 - 87
  • [33] Intra-Arterial Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) DOTATATE for Neuroendocrine tumour Liver dominant metastatic disease -Initial experience
    Das, Subha
    Kumar, Saurabh
    Sen, Ishita
    Thakral, Parul
    Pant, Vineet
    Sharma, Kanchan
    Manda, Divya
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Peptide Receptor Radionuclide Therapy Using 177Lu and 90Y-DOTATATE in Metastatic Treatment-Refractory Medullary Thyroid Cancer
    Puranik, A.
    Baum, R. P.
    Kulkarni, H.
    Singh, A.
    Rangarajan, V
    Agrawal, A.
    Shah, S.
    Purandare, N.
    NEUROENDOCRINOLOGY, 2019, 108 : 228 - 228
  • [35] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [36] Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
    Edgar J. Rolleman
    Marleen Melis
    Roelf Valkema
    Otto C. Boerman
    Eric P. Krenning
    Marion de Jong
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 1018 - 1031
  • [37] Toxicity, Response and Survival Analyses of Peptide Receptor Radionuclide Therapy (PRRT) in Treatment Refractory Metastatic Thyroid Cancer Using Yttrium-90 and Lutetium-177 Labeled Somatostatin Analogs
    Prasad, V
    Budiawan, H.
    Ali, S.
    Hoersch, D.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 52 - 53
  • [38] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09) : 1337 - 1340
  • [39] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Nautiyal, Amit
    Michopoulou, Sofia
    Guy, Matt
    CLINICAL AND TRANSLATIONAL IMAGING, 2024, 12 (02) : 157 - 175
  • [40] Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
    Rolleman, Edgar J.
    Melis, Marleen
    Valkema, Roelf
    Boerman, Otto C.
    Krenning, Eric P.
    de Jong, Marion
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (05) : 1018 - 1031
12345